Dr. Gater’s Weight Loss & Wellness marketed compounded semaglutide and tirzepatide with false or misleading FDA-approval and generic-Ozempic claims.
What happened
In September 2025, FDA reviewed the website https://drgatergetsresults.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said the site made claims such as “FDA Approved,” “Generic Ozempic,” and “generic version of Ozempic/Wegovy,” which imply the compounded products are the same as FDA-approved drugs when they are not. FDA cited these claims as false or misleading and as misbranding.
What FDA found
The website said the compounded semaglutide and tirzepatide products were “FDA Approved,” but compounded drug products are not FDA-approved.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]The website called semaglutide a “generic version” or “generic equivalent” of Ozempic/Wegovy, implying it is the same as an FDA-approved product.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]The website used “Generic Ozempic” and similar language that FDA says falsely or misleadingly suggests the compounded product is an FDA-approved generic.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]FDA listed the website claim “Tirzepatide is the active ingredient in Mounjaro” among claims that imply the compounded product is the same as an FDA-approved product.
FDCA section 502(a) [21 U.S.C. § 352(a)] and section 502(bb) [21 U.S.C. § 352(bb)]FDA said introducing or delivering these misbranded drugs into interstate commerce is prohibited.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA also said receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, FDA asks the company to send OCQC in CDER’s Office of Compliance a written response describing specific steps taken to address the violations, prevent recurrence, and include related documentation. If the company cannot completely address the matter in that time, it must state the reason for delay and when it will.
Who should pay attention
- telehealth weight-loss clinics selling compounded semaglutide or tirzepatide
- compounding pharmacies and partner pharmacies named in such promotions
- companies advertising compounded drugs as FDA-approved or generic equivalents
This is a summary. Read the original letter on fda.gov.